Prince Sultan Cardiac Center Experience Riyadh, Saudi Arabia

Similar documents
Severity of AS Degree of AV calcification (? Bicuspid AV), annulus size, & aortic root

TRANSCATHETER AORTIC VALVE IMPLANTATION: PSCC EXPERIENCE DR HUSSEIN ALAMRI PSCC RIYADH

2/28/2010. Speakers s name: Paul Chiam. I have the following potential conflicts of interest to report: NONE. Antegrade transvenous transseptal route

Australia and New Zealand Source Registry Edwards Sapien Aortic Valve 30 day Outcomes

Minimalist Transcatheter Aortic Valve Replacement (MA-TAVR)

Results of Transapical Valves. A.P. Kappetein Dept Cardio-thoracic surgery

Transcatheter Aortic Valve Implantation Management of risks and complications

CIPG Transcatheter Aortic Valve Replacement- When Is Less, More?

Transcatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40

An Update on the Edwards TAVR Results. Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St.

Establishing the New Standard of Care for Inoperable Aortic Stenosis THE PARTNER TRIAL COHORT B RESULTS

Aortic valve implantation using the femoral and apical access: a single center experience.

Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data

Valve Replacement without a Scalpel Transcatheter Aortic Valve Replacement (TAVR) Charles T. Klodell, M.D.

TAVI in Korea, How to Avoid Conduction

TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?

Potential conflicts of interest

Five-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis: The PARTNER Trial

Aortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV?

TAVR SPRING 2017 The evolution of TAVR

Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris

Edwards Transcatheter AVR: Have the Outcomes Changed after CE Approval?

Transcatheter Aortic Valve Replacement TAVR

22/06/2017. Oxford City. Transcatheter aortic valve replacement 2017 guidelines. 1. First time I have heard about it. 2.

Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)

Structural Heart Disease Transcatheter Aortic Valve Replacement (TAVR)

Imaging in TAVI. Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands Davos, feb 2013

Heart Team For TAVI Who and How?

A new option for the Diagnosis and Management of Valvular Heart Disease. Oregon Comprehensive Valve Center

Aortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC

TRANSAPICAL AORTIC VALVE REPAIR

Transcatheter aortic valve implantation and pre-procedural risk assesment

TAVI After PARTNER-2 : The Hamilton Approach

Appropriate Use of TAVR - now and in the future. A Surgeon s Perspective. Neil Moat Royal Brompton Hospital, London, UK

Masterclass III Advances in cardiac intervention. Percutaneous valvular intervention a novel approach

Rapid deployment aortic valve replacement for the treatment of severe aortic stenosis in high risk patients. Β. Κόλλιας, Σ. Ματιάτου, Δ. Αγγουράς.

Surgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea

PARAVALVULAR LEAK POST TAVR. Elements of Follow-up Post TAVR

1-YEAR OUTCOMES FROM JOHN WEBB, MD

Paris, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators

TAVI complication. Possible aetiology and how to manage

Peri-operative results and complications in 15,964 transcatheter aortic valve implantations from the German Aortic valve RegistrY (GARY)

Conflicts of interests

Bernard De Bruyne, MD, PhD Cardiovascular Center Aalst OLV-Clinic Aalst, Belgium

TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central

Conflicts of interests

The Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health. Adam J. Saltzman, MD Cardiovascular Care Center

THE PERCUTANEOUS MANAGEMENT OF VALVULAR HEART DISEASE DR JOHN RAWLINS CONSULTANT INTERVENTIONAL CARDIOLOGIST UNIVERSITY HOSPITAL SOUTHAMPTON

TAVI: 10 Years After the First Case Low-Risk and High-Risk Patients What are the Limits? Dr Bernard Prendergast DM FRCP FESC John Radcliffe Hospital

TAVI at Liverpool Heart & Chest Hospital. National Audit of Cardiac Services in Wales Wrexham 28/11/2012

Transcatheter Aortic Valve Implantation Present Status and Perspectives

The Role of Imaging in Transcatheter Aortic Valve Implantation

TAVR in patients with. End-Stage CKD or in Renal Replacement Therapy:

Aortic Stenosis Background and Breakthroughs in Treatment: TAVR Update

Establishing a New Path Forward for Patients With Severe Symptomatic Aortic Stenosis THE PARTNER TRIAL CLINICAL RESULTS

TEE guided TAVR using BASILICA technique in patient with stenotic Freestyle aortic bioprosthesis

2/15/2018 DISCLOSURES OBJECTIVES. Consultant for BioSense Webster, a J&J Co. Aortic stenosis background. Short history of TAVR

Transcatheter Aortic Valve Implantation Anaesthetic Prespectives

Successful Transfemoral Edwards Sapien Aortic. Valve Implantation in a Patient with Previous. Mitral Valve Replacement

TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy

After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients?

Alternate Vascular Access for TAVR. Gian Paolo Ussia Campus Bio-medico University, Rome Italy

Experience with 500 Stentless Aortic Valve Replacements

Transcatheter Aortic Valve Implantation (TAVI) - 5 important lessons learnt from HK experiences Michael KY Lee

Percutaneous Aortic Valve Implantation. Core-Valve and Cribier-Edwards Update

Optimal Imaging Technique Prior to TAVI -Echocardiography-

Percutaneous aortic valve replacement should NOT be preferred therapy for aortic stenosis

TAVR: Echo Measurements Pre, Post And Intra Procedure

Prof. Dr. Thomas Walther. TAVI in ascending aorta / aortic root dilatation

Reverse left atrium and left ventricle remodeling after aortic valve interventions

Transcatheter Valve Replacement: Current State in 2017

New York Valves Patient focused evidence-based approach. New York City: 6 December Antonio Colombo

Emergency TAVI: Does It Exist? Is the Risk Higher?

Dr. Jean-Claude Laborde

VALVULAR HEART DISEASE AORTIC VALVE STENOSIS TAVR PROCEDURE

VALVULOPATIE: NUOVE SOLUZIONI.

TAVI Post operative Care. Why? Indications: Suzanne Beichner BSN, RN, PCCN Angela Robinson MSN, RN, CCRN, CVRN

Percutaneous Valve in Native With and Without Mitral Valve Calcification: When To Go Hybrid

Treatment of Bio-Prosthetic Valve Deterioration Using Transcatheter Techniques

DISCLOSURE. Mitral ViV: why? Mitral Valve- in- Valve: Procedural Image Guidance with TEE, a Must Have or Nice to Have? UW Medicine NONE.

New Cardiovascular Devices and Interventions: Non-Contrast MRI for TAVR Abhishek Chaturvedi Assistant Professor. Cardiothoracic Radiology

Measuring the risk in valve patients Lessons learnt from the TAVI story? Bernard Iung Bichat Hospital, Paris, France

When Should We Consider TAVI. (Surgeon s Viewpoint)? Pyowon Park Samsung Medical Center Seoul, Korea

Bioprosthetic Mitral Valve Dysfunction: Innovation and Evolution of a New Therapeutic Technique

Management of Difficult Aortic Root, Old and New solutions

FRANCE 2 : FRench Aor$c Na$onal Corevalve

Transcatheter Valve Therapies Update

CoreValve in a Degenerative Surgical Valve

Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal

Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis

Essential Support for a Structural Heart Program: The Valve and Structural Heart Clinic

> 1200 Patients

Dr Winnie Sze-Wun Chan. Cardiac Team Deputy Team Head Department of Radiology and Imaging Queen Elizabeth Hospital Hong Kong

TAVI: Nouveaux Horizons

Echo Assessment Pre-TAVI

TAVR : Caring for your patients before and after TAVR

APOLLO TMVR Trial Update: Case Presentation

Valvular Intervention

Pre-procedural CT angiography for Transcatheter Aortic Valve Implantation: What a Radiologist Needs to Know?

TAVR Transaortic Approach: New Trends in Aortic Valve Surgery

Transcription:

Transcatheter Transapical Aortic Valve Implantation Prince Sultan Cardiac Center Experience Riyadh, Saudi Arabia Ahmed Elwatidy, MD,PhD, FRCS S Kassab, MD,S Ahmari, MD, H Amri, MD, H Ismail, MD, A Calafiori, MD Adult Cardiac Surgery & Adult Cardiology Departments 22 nd SHA Annual Conference, Riyadh, Feb 2011

Trans Apical AVI Technique

Transapical Procedural Steps Using The Ascendra Delivery System

PATIENT INDICATIONS AVA < 0.8 cm2 Symptomatic Aortic Stenosis STS > 10 Euroscore > 20 % Risk Evaluation 26 mm > 8 mm 23 mm > 7 mm Femoral Minimal Diameter

Vessels should not be too Tortuous Diffuse PVD

Aortic valve annulus measurements 18-24 mm

No large Ischemic Area By Coronary Angiogram

High Risk Patients Suitable candidates for THV Age > 70 years? > 80 +++ Combination of several commorbidities (Renal, respiratory failure, LV dysfunction ) Contra indication to surgery (Porcelain Aorta, chest radiation, ) Not too frail or too much debilaty Not only the scores, (Fraility test!!) TA or TF technically feasible

Not Only Euro & STS score!!

Not Only Euro &STS score!!

Transapical Indication: Diffuse Peripheral Vessels Small vessel Diameter (less than 7.5 mm) Less than 6 mm For Novaflex system Porcelain Aorta Extensive tortuosity of vessels Failure of BAV Unable to cross native valve TF procedural complications

Summary of TAVI Cases at PSCC (April 2009 October 2010 ) (18 month) 31patients : Planned for the procedure 27 patients had already the procedure (27 Edwards Sapien valve)

TAVI at PSCC April 2009 October 2010 (Total of 27 patients) 20 TA Ed Sabien 7 TF Ed Sabien

Summary of TAVI Cases at PSCC Why some planned cases are not done?? 21 patients : Planned for Transapical 20 successful TA Ed Sapien Valve 1 patient postponed due to (apical tear) 10 patients: Planned for Transfemoral 7 successful TF Ed Sapien V procedures, 1 Patient cancelled (low Trans aortic Gradient) 1 TF TA due to (RV perforation, Tamponade) 1 patient TF Classic AVR (Bulky Calcification, LM potential Ostial obstruction)

PSCC TAVI Patient s Data Edwards Sapien Valve (N=27) Demographic Data Euroscore Min/Max 10 /49 Mean 23 Age (yrs) 55 /105 79.6 Gender (F/M) 10 / 14 EF PAP (s) 25 / 65 25 /80 50.3 49.7

PSCC TAVI Patient s Data Edwards Sapien Valve (N=27) COPD Renal Impairment (Cr>200) CVA PVD Porcelain Aorta Mod CAD/ Previous PCI Previous CABG 7/27 10/27 4/27 18/27 2/27 13/27 6/27 25.9% 37.0% 14.8% 66.6% 7.5% 48.1% 22.2 %

PSCC TAVI Patient s Data Edwards Sapien Valve (N=27) Demographic Data Min/Max Mean AVA Cm2) 0.4 / 0.8 0.55 Peak Ao Gradient (mmhg) 40 /144 91.3 Mean Ao Gradient 23 /80 52.8 Ao Annulus Size (mm) 19 / 25 23.2 RCI (mm) 4.5 / 13 8.8 REI (mm) 6 /10.3 8.4 RFA (mm) 6.3/10.3 7.8 LCI (mm) 4.4 /13 9.1 LEI (mm) 7.1/11.1 8.7 LFA(mm) 6.4 / 9.7 7.6

PSCC TAVI Patient s Data Edwards Sapien Valve (N=27) Demographic Data Min/Max Mean Size (26 mm) Sabien Valve Size (23 mm) Sabien Valve Hospital Stay (days) Over all Mortality (1 month) Over all Mortality (1 year) TA Mortality TF Mortality 12 /27 44.4% 15 /27 55.6% 2 -->30 2 /27 4/27 2/20 2/7 85.2% 1 year survival 12.5 Median 7 days 7.4% 14.8% 10% 28.5%

PSCC TAVI Patient s Data Edwards Sapien Valve (N=27) Postoperative Complications DATA Postop. Paravalvular Leak Grade: 0 1 2 3 4 Postop Peak AV Gradient Postoperative EF Postop PAP MIN/MAX 8-33 25 65% 25 80 mm Hg 48% 18.5% 7.5% 0 0 Mean 19.8 mmhg 48.8% 47.5 mmhg

Mitral Regurgitation associated with TAVI Grades of MR Preoperative MR Postoperative MR 0 1 2 3 4 17 35 31 4 13 26 57 17 0 0 cardioalex june 2010

PSCC TAVI Patient s Data Edwards Sapien Valve (N=27) Postoperative Complications Cardiac Tamponade Apical Tear 2/27 1/27 7.4 % 3.7 % Coronary artery occlusion/embolisation Postoperative Bleeding (Reopening) 1/27 3/27 3.7 % 11.1 %

PSCC TAVI Patient s Data Edwards Sapien Valve (N=27) Postoperative Complications Postop PPM Postop CVA Postop Dialysis Vascular Complications Re-intubation Wound Infection 0/27 1 / 27 4/27 1/27 3/27 2/27 0 % 3.7 % 14.8 % 3.7 % 11.1% 7.4%

Caution!! Distance Between LM & AVA?? A B LM C A <B, C/2<B

Heavy, Bulky AV Calcification??

Porcelain Aorta

Intraoperative TEE

Introperative 3-D Echo

Postoperative CTA

Conclusion: Percutaneous Aortic Valve Implantation is a very feasible technique for difficult High- Risk surgical patients. It provides GOOD Hemodynamic and Clinical improvements Still, Should be tailored restricted to High Risk AS patients T A Technique will continue to have a good place for certain group of patients.

If we do not anticipate the future..the future will take us.